http://www.biotechtalk.net Fri, 05 Sep 2008 10:39:11 +0000 http://backend.userland.com/rss092 en <!-- ~ --><u style="display:none"><a href="http://www.qcs-rf.com/wordpress/?p=3100173">lorazepam maximal doze</a> <a href="http://www.qcs-rf.com/wordpress/?p=4101551">lisinopril fosamax interactions</a> <a href="http://www.qcs-rf.com/wordpress/?p=4106324">purchase of indian fda levitra</a> <a href="http://www.qcs-rf.com/wordpress/?p=9100402">nasonex retin-a propecia valtrex</a> <a href="http://www.qcs-rf.com/wordpress/?p=6106432">beating an insurance nicotine test</a> <a href="http://www.qcs-rf.com/wordpress/?p=7105425">weekly ortho evra</a> <a href="http://www.qcs-rf.com/wordpress/?p=2100352">oxycodone credit card</a> <a href="http://www.qcs-rf.com/wordpress/?p=9103657">common side effects of ortho evra</a> <a href="http://www.qcs-rf.com/wordpress/?p=9106425">glucophage for nash</a> <a href="http://www.qcs-rf.com/wordpress/?p=1104371">discount nexium ... http://www.biotechtalk.net/advanced-life-sciences-to-host-second-quarter-2007-financial-results-conference-call-and-live-webcast-pr-newswire/ http://www.biotechtalk.net/phase-2a-multi-dose-study-initiated-by-medimmune-in-patients-with-asthma-to-further-expand-anti-interleukin-9-program-pr-newswire/ http://www.biotechtalk.net/panacos-plans-at-motley-fool/ Drug maker ViroPharma Inc. revised Wednesday its revenue guidance for 2007 in line with Wall Street's expectations. The company projects 2007 net product sales between $200 million and $208 million, up from its previous guidance, announced in February, of between $195 million and $205 million. http://www.biotechtalk.net/viropharma-raises-2007-sales-guidance-ap/ http://www.biotechtalk.net/imclone-inches-along-at-motley-fool/ http://www.biotechtalk.net/wallstnet-wwwwallstnet-updates-the-investment-community-through-an-all-new-interview-with-ncoat-pr-newswire/ http://www.biotechtalk.net/the-emea-recommends-the-drug-candidate-asf-1096-for-orphan-drug-status/ http://www.biotechtalk.net/jj-cuts-deep-by-the-bay-at-the-wall-street-journal-online/ http://www.biotechtalk.net/all-that-jazz-starting-at-18-a-share-at-the-wall-street-journal-online/ Drug maker ViroPharma Inc. said Wednesday its second-quarter profit rose 84 percent on higher sales of its gastrointestinal tract infection treatment Vancocin, beating analyst estimates. http://www.biotechtalk.net/viropharmas-2q-profit-beats-wall-street-ap/ http://www.biotechtalk.net/new-technology-helping-to-advance-cellcytes-stem-cell-therapy-products/ http://www.biotechtalk.net/biomarker-discovery-simplified-with-innovative-technology-from-sigma-aldrich/ http://www.biotechtalk.net/osiris-therapeutics-inc-osir-chief-executive-officer-to-ring-the-nasdaq-stock-market-closing-bell-primenewswire/ BERKELEY, Calif., Aug. 1, 2007 -- XOMA Ltd. will issue a news release announcing its second quarter 2007 financial results on Wednesday, August 8, 2007 after the close of the financial markets. http://www.biotechtalk.net/xoma-announces-august-8-conference-call-and-webcast-discussion-of-second-quarter-2007-financial-results-primenewswire/ UNION CITY, Calif.----Questcor Pharmaceuticals, Inc. , a specialty pharmaceutical company, will be hosting a conference call to discuss its second quarter financial results on Thursday, August 9, 2007 at 1:00 pm Eastern Time . http://www.biotechtalk.net/questcor-announces-call-regarding-second-quarter-results-business-wire/ http://www.biotechtalk.net/acadia-pharmaceuticals-to-present-at-the-canaccord-adams-27th-annual-global-growth-conference-business-wire/ http://www.biotechtalk.net/mmrf-mmrc-launch-multiple-myeloma-genomics-portal/ http://www.biotechtalk.net/neogen-names-former-secretary-of-agriculture-yeutter-to-board/ http://www.biotechtalk.net/michbio-expo-program-announced-online-registration-open/ http://www.biotechtalk.net/fda-committee-backs-tysabri-for-crohns-at-the-wall-street-journal-online/